A potentially more effective treatment for HER2 mutant metastatic breast cancer
A phase II clinical trial is on its way to assess the value of poziotinib in the treatment of this devastating condition.
Read More
neratinib
A new HER2 mutation leads to a clinical trial and to a promising diagnostic tool for metastatic breast cancer
There is a group of metastatic breast cancers that has the HER2 gene amplified – the cells have many copies of it – which leads
Read More